Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice.
<h4>Aims</h4>Asthma is characterized by chronic airway inflammation, persistent cough, wheezing, and dyspnea. This study aimed to evaluate the efficacy of Limosilactobacillus reuteri VHProbi® M07 (M07) administration in alleviate the asthma severity in a mice model.<h4>Methods and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0317587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540234651271168 |
|---|---|
| author | Guoqing Meng Hongchang Cui Congrui Feng Chaoqun Guo Lei Song Zhi Duan |
| author_facet | Guoqing Meng Hongchang Cui Congrui Feng Chaoqun Guo Lei Song Zhi Duan |
| author_sort | Guoqing Meng |
| collection | DOAJ |
| description | <h4>Aims</h4>Asthma is characterized by chronic airway inflammation, persistent cough, wheezing, and dyspnea. This study aimed to evaluate the efficacy of Limosilactobacillus reuteri VHProbi® M07 (M07) administration in alleviate the asthma severity in a mice model.<h4>Methods and results</h4>In vitro studies confirmed that M07 can survive and proliferate within the gastrointestinal tract. BALB/c mice were administered M07 both before and after ovalbumin (OVA) challenge. Serum levels of OVA-specific immunoglobulin (Ig) E and IgG1, inflammatory cells and cytokines in bronchoalveolar lavage fluid were assessed, along with histopathological examination of lung tissue. Compared to the placebo (PLA) group, mice treated with M07 exhibited significantly lower levels of OVA-specific IgE and IgG1 (P < 0.01). The counts of eosinophils and neutrophils were also significantly reduced in both the pretreated (PRE) group and post-treated (POS) group compared with the PLA group (P < 0.01). Histological analysis of lung tissues verified the protective effects of M07 against inflammation, demonstrating reduced infiltration of inflammatory cells. Additionally, mice in the PRE and POS groups showed significantly increased levels of IL-10 (P < 0.01), and significantly decreased levels of IL-5, IL-13, MCP-1, eotaxin, and tumor necrosis factor-α (P < 0.01).<h4>Conclusions</h4>Oral administration of M07 mitigated key features of inflammatory responses in the OVA-induced mice asthma model. These findings suggest that M07 holds therapeutic potential for the treatment of allergic asthma. |
| format | Article |
| id | doaj-art-273db49bf9f64e88bb61084f877ed9e3 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-273db49bf9f64e88bb61084f877ed9e32025-02-05T05:31:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031758710.1371/journal.pone.0317587Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice.Guoqing MengHongchang CuiCongrui FengChaoqun GuoLei SongZhi Duan<h4>Aims</h4>Asthma is characterized by chronic airway inflammation, persistent cough, wheezing, and dyspnea. This study aimed to evaluate the efficacy of Limosilactobacillus reuteri VHProbi® M07 (M07) administration in alleviate the asthma severity in a mice model.<h4>Methods and results</h4>In vitro studies confirmed that M07 can survive and proliferate within the gastrointestinal tract. BALB/c mice were administered M07 both before and after ovalbumin (OVA) challenge. Serum levels of OVA-specific immunoglobulin (Ig) E and IgG1, inflammatory cells and cytokines in bronchoalveolar lavage fluid were assessed, along with histopathological examination of lung tissue. Compared to the placebo (PLA) group, mice treated with M07 exhibited significantly lower levels of OVA-specific IgE and IgG1 (P < 0.01). The counts of eosinophils and neutrophils were also significantly reduced in both the pretreated (PRE) group and post-treated (POS) group compared with the PLA group (P < 0.01). Histological analysis of lung tissues verified the protective effects of M07 against inflammation, demonstrating reduced infiltration of inflammatory cells. Additionally, mice in the PRE and POS groups showed significantly increased levels of IL-10 (P < 0.01), and significantly decreased levels of IL-5, IL-13, MCP-1, eotaxin, and tumor necrosis factor-α (P < 0.01).<h4>Conclusions</h4>Oral administration of M07 mitigated key features of inflammatory responses in the OVA-induced mice asthma model. These findings suggest that M07 holds therapeutic potential for the treatment of allergic asthma.https://doi.org/10.1371/journal.pone.0317587 |
| spellingShingle | Guoqing Meng Hongchang Cui Congrui Feng Chaoqun Guo Lei Song Zhi Duan Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. PLoS ONE |
| title | Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. |
| title_full | Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. |
| title_fullStr | Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. |
| title_full_unstemmed | Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. |
| title_short | Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. |
| title_sort | oral administration of limosilactobacillus reuteri vhprobi r m07 alleviates ovalbumin induced allergic asthma in mice |
| url | https://doi.org/10.1371/journal.pone.0317587 |
| work_keys_str_mv | AT guoqingmeng oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice AT hongchangcui oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice AT congruifeng oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice AT chaoqunguo oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice AT leisong oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice AT zhiduan oraladministrationoflimosilactobacillusreuterivhprobim07alleviatesovalbumininducedallergicasthmainmice |